2. Search Result
Search Result
Isoforms Recommended: MAP4K1/HPK1
Results for "

HPK1

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148847
    HPK1-IN-32

    		MAP4K Cancer
    HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC50 of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases [1].
    HPK1-IN-32
  • HY-144093
    HPK1-IN-26

    		MAP4K Infection
    HPK1-IN-26 is a HPK1 and GLK inhibitor extracted from patent WO2021254118A1 compound 1. HPK1-IN-26 can be used for the research of animal pathogen infection [1].
    HPK1-IN-26
  • HY-145107
    HPK1-IN-19

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-19 (Compound I-47) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor [1].
    HPK1-IN-19
  • HY-153553
    HPK1 antagonist-1

    		MAP4K Inflammation/Immunology Cancer
    HPK1 antagonist-1 (I-792) is an Hpk1 antagonist that can be used in the study of cancer and immune disease [1].
    HPK1 antagonist-1
  • HY-168283
    HPK1 ligand 2

    		Ligands for Target Protein for PROTAC Cancer
    HPK1 ligand 2 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). HPK1 ligand 2 can be used for synthesis DD205-291 (HY-168282) [1].
    HPK1 ligand 2
  • HY-162841
    HPK1 ligand 1

    		Ligands for Target Protein for PROTAC Cancer
    HPK1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HPK1 ligand 1 can be used for synthesis PROTAC PD-L1 degrader-2 (HY-162816) [1].
    HPK1 ligand 1
  • HY-156508
    HPK1-IN-37

    		MAP4K Cancer
    HPK1-IN-37 (compound A85) is an inhibitor of HPK1 (IC50=3.7 nM). HPK1-IN-37 can be used for research in HPK1 related disorders or diseases including cancers [1].
    HPK1-IN-37
  • HY-160217
    HPK1-IN-41

    		MAP4K Cancer
    HPK1-IN-41 (compound Z389) is an inhibitor of HPK1 with an IC50 value of 0.21 nM [1].
    HPK1-IN-41
  • HY-145109
    HPK1-IN-20

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-20 (Compound 106) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor [1].
    HPK1-IN-20
  • HY-152257
    HPK1-IN-31

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-31 (compound 5i) is an orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunoresearch [1].
    HPK1-IN-31
  • HY-172594
    HPK1-IN-57

    		MAP4K Interleukin Related Inflammation/Immunology Cancer
    HPK1-IN-57 (Compound 10c) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 0.09 nM. HPK1-IN-57 inhibits the activity of HPK1 kinase, hindering the phosphorylation of the downstream adaptor protein SLP76 (IC50 is 33.74 nM) and effectively stimulating the secretion of the T cell activation marker IL-2 (EC50 is 84.24 nM). HPK1-IN-57 is promising for research of tumor immunotherapy [1].
    HPK1-IN-57
  • HY-144091
    HPK1-IN-24

    		MAP4K Cancer
    HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a Ki of 100 nM. HPK1-IN-24 has the potential for cancer research [1].
    HPK1-IN-24
  • HY-144092
    HPK1-IN-25

    		MAP4K Cancer
    HPK1-IN-25 (example 94) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a enzymatic activity IC50 of 129 nM. HPK1-IN-25 has the potential for cancer research [1].
    HPK1-IN-25
  • HY-168110
    HPK1-IN-52

    		MAP4K Cancer
    HPK1-IN-52 is a potent and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 10.4 nM. HPK1-IN-52 exhibits anti-tumor activities [1].
    HPK1-IN-52
  • HY-163717
    HPK1-IN-48

    		MAP4K Cancer
    HPK1-IN-48 (compound 14g) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a IC50 of 0.15 nM. HPK1-IN-48 significantly suppresses the phosphorylation of SLP76 with a IC50 of 27.92 nM [1].
    HPK1-IN-48
  • HY-149206
    HPK1-IN-33

    		MAP4K Cancer
    HPK1-IN-33 (compound 21) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a Ki value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC50s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively [1].
    HPK1-IN-33
  • HY-145039
    HPK1-IN-13

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-13 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) [1].
    HPK1-IN-13
  • HY-145038
    HPK1-IN-12

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-12 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) [1].
    HPK1-IN-12
  • HY-145040
    HPK1-IN-14

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-14 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) [1].
    HPK1-IN-14
  • HY-145035
    HPK1-IN-9

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) [1].
    HPK1-IN-9
  • HY-145037
    HPK1-IN-11

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-11 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) [1].
    HPK1-IN-11
  • HY-145036
    HPK1-IN-10

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) [1].
    HPK1-IN-10
  • HY-170365
    HPK1-IN-55

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-55 (compound 19) is a selective and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 of <0.51 nM. HPK1-IN-55 shows excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK). HPK1-IN-55 has anticancer effects [1].
    HPK1-IN-55
  • HY-143869
    HPK1-IN-28

    		MAP4K Cancer
    HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) [1].
    HPK1-IN-28
  • HY-143870
    HPK1-IN-29

    		MAP4K Cancer
    HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) [1].
    HPK1-IN-29
  • HY-145041
    HPK1-IN-15

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-15 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2018049200A1, compound 50) [1].
    HPK1-IN-15
  • HY-145042
    HPK1-IN-16

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-16 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019051199A1, compound 39) [1].
    HPK1-IN-16
  • HY-145044
    HPK1-IN-17

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-17 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 73) [1].
    HPK1-IN-17
  • HY-145045
    HPK1-IN-18

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-18 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-18 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 1) [1].
    HPK1-IN-18
  • HY-138568
    HPK1-IN-3

    		MAP4K Inflammation/Immunology
    HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs) [1].
    HPK1-IN-3
  • HY-143868
    HPK1-IN-27

    		MAP4K Cancer
    HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) [1].
    HPK1-IN-27
  • HY-143871
    HPK1-IN-30

    		MAP4K Cancer
    HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) [1].
    HPK1-IN-30
  • HY-132150A
    HPK1-IN-2 dihydrochloride

    		MAP4K FLT3 Src Cancer
    HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC50<0.5 µΜ) and Flt3 (IC50<0.05 µΜ) kinase activities [1].
    HPK1-IN-2 dihydrochloride
  • HY-160218
    HPK1-IN-42

    		MAP4K Cancer
    HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC50 50 of 0.24 nM [1].
    HPK1-IN-42
  • HY-149773S
    HPK1-IN-40-d2

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC50 of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity [1].
    HPK1-IN-40-d2
  • HY-162545
    HPK1-IN-47

    		MAP4K Ligands for Target Protein for PROTAC Cancer
    HPK1-IN-47 is a HPK1 ligand. HPK1-IN-47 can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-2 (HY-162544). HPK1-IN-47 can be used for research of HPK1-mediated diseases including cancer [1].
    HPK1-IN-47
  • HY-149520
    HPK1-IN-39

    		MAP4K Cancer
    HPK1-IN-39 (Compound 10n) is a selective HPK1 Inhibitor (IC50: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy [1].
    HPK1-IN-39
  • HY-144073
    HPK1-IN-21

    		MAP4K Cancer
    HPK1-IN-21 is a potent inhibitor of HPK1 kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active [1].
    HPK1-IN-21
  • HY-172674
    HPK1-IN-59

    		MAP4K Cancer
    HPK1-IN-59 (compound 39) is an orally active HPK1 inhibitor with an IC50 of 0.70 nM. HPK1-IN-59 has favorable oral bioavailability in mice [1].
    HPK1-IN-59
  • HY-156509
    HPK1-IN-38

    		MAP4K Others
    HPK1-IN-38 (compound 15) is a MAP4K1/HPK1 inhibitor，can be used for HPK1 related disorders research [1].
    HPK1-IN-38
  • HY-163496
    HPK1-IN-45

    		MAP4K Cancer
    HPK1-IN-45 (Compound 3) is a HPK1 inhibitor, with an IC50 of 0.3 nM. HPK1-IN-45 inhibits SLP-76 phosphorylation (IC50 = 57.52 nM) and IL-2 release (IC50 = 38 nM). HPK1-IN-45 can be used for the research of cancer [1].
    HPK1-IN-45
  • HY-172875
    HPK1-IN-58

    		MAP4K Interleukin Related Inflammation/Immunology Cancer
    HPK1-IN-58 is an inhibitor of HPK1 (IC50: 2.6 nM) and SLP76 (IC50: 20 nM). HPK1-IN-58 enhances IL-2 secretion and reverses PGE2-induced immunosuppression. HPK1-IN-58 can be used in anti-tumor immunity research [1].
    HPK1-IN-58
  • HY-132926
    HPK1-IN-8

    		MAP4K Cancer
    HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1.
    HPK1-IN-8
  • HY-149232
    HPK1-IN-35

    		MAP4K Cancer
    HPK1-IN-35 is a potent and selective HPK1 inhibitor with an IC50 value of 3.5 nM. HPK1-IN-35 decreases the expression of p-SLP76 and promotes IL-2 secretion [1].
    HPK1-IN-35
  • HY-172107
    HPK1-IN-56

    		MAP4K Interleukin Related Inflammation/Immunology Cancer
    HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody [1].
    HPK1-IN-56
  • HY-153448
    HPK1-IN-36

    		MAP4K Cancer
    HPK1-IN-36 (compound 2) is a potent HPK1 inhibitor with an IC50 value of 0.5 nM [1].
    HPK1-IN-36
  • HY-168119
    HPK1-IN-53

    		MAP4K Cancer
    HPK1-IN-53 (compund 3a) is the potent HPK1 inhibitor (IC50=48 nM) [1].
    HPK1-IN-53
  • HY-161335
    HPK1-IN-43

    		MAP4K Interleukin Related IFNAR Cancer
    HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC50 value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research [1].
    HPK1-IN-43
  • HY-159905
    HPK1-IN-54

    		MAP4K Inflammation/Immunology
    HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC50 value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy [1].
    HPK1-IN-54
  • HY-163495
    HPK1-IN-44

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-44 (Compound 1) is an inhibitor of HPK1 (IC50=0.1 nM (40 μM ATP)) [1].
    HPK1-IN-44

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: